← All stocks

Cyclerion Therapeutics, Inc.

CYCN Net buying
CIK 0001755237 #5052 in the set updated 22 Sep 2026
Bought (120 mo)
$33.01M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$795.13K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$795.13K
10 of 10 sales
Net
+$32.21M
+$32.21M against sales at will

By person

21 insiders · 27 transactions

There is no salary here to measure against. Cyclerion Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
MCGUIRE TERRANCE
Director
$10.32M (4)
$27.16 (1)
+$10.32M
741,806
15.85%
$1.15M
SCHULMAN AMY W
Director
$10.02M (2)
+$10.02M
633,625
13.54%
$982.82K
Hecht Peter M
Director
$5.13M (4)
+$5.13M
912,180
19.49%
$1.41M
Currie Mark G
President and CSO
$4.00M (1)
$186.27K (3)
+$3.81M
251,648
5.38%
$390.33K
Slate Path Capital LP entity
10% owner
$3.00M (1)
$555.11K (1)
+$2.44M
7,157,601
$11.10M
+9.2%
Busch Andreas
Chief Scientific Officer
$543.75K (2)
+$543.75K
254,704
5.44%
$395.07K
+5,315%
Huyett William
Chief Financial Officer
$35.91K (3)
−$35.91K
67,590
1.44%
$104.84K
+4,756%
Wright Christopher I
Chief Medical Officer
$10.52K (1)
−$10.52K
42,728
0.9127%
$66.28K
−5.8%
Gjino Anjeza
Chief Financial Officer
$7.30K (1)
−$7.30K
31,599
0.6750%
$49.01K
−5.5%
Graul Regina Margaret
See Remarks
107,523
2.30%
$166.78K
+113.8%
Higgins Michael J
Director
30,740
0.6566%
$47.68K
+42.0%
DESOUZA ERROL B
Director
30,000
0.6408%
$46.53K
CHICKO RHONDA M.
Chief Financial Officer
25,018
0.5344%
$38.81K
+138,889%
Hyman Steven
Director
20,000
0.4272%
$31.02K
Fanucci Marsha
Director
16,950
0.3621%
$26.29K
CONRADES GEORGE H
Director
2,421
0.0517%
$3.76K
Lovell Stephanie
Director
2,421
0.0517%
$3.76K
Mendelsohn Michael
Director
2,421
0.0517%
$3.76K
Isacson Ole
Director
2,421
0.0517%
$3.76K
Churchwell Kevin
Director
2,421
0.0517%
$3.76K
IRONWOOD PHARMACEUTICALS INC entity
10% owner
0
0.0000%
$0.00
−100.0%
Insider
Date
Role
Action
Shares
Price
Amount
Slate Path Capital LP
3 Jun 2021
10% owner
Buy indirect
961,538
$3.12
$3.00M
Hecht Peter M
3 Jun 2021
Chief Executive Officer
Buy
823,170
$3.28
$2.70M
MCGUIRE TERRANCE
3 Jun 2021
Director
Buy indirect
3,322
$3.12
$10.36K
MCGUIRE TERRANCE
3 Jun 2021
Director
Buy indirect
92,831
$3.12
$289.63K
Hecht Peter M
6 May 2021
Chief Executive Officer
Buy
302,000
$2.43
$733.86K
Hecht Peter M
5 May 2021
Chief Executive Officer
Buy
398,001
$2.53
$1.01M
Hecht Peter M
4 May 2021
Chief Executive Officer
Buy
300,000
$2.29
$687.00K
Busch Andreas
9 Nov 2020
Chief Innovation Officer
Buy
125,000
$2.53
$316.25K
Busch Andreas
15 Nov 2019
Chief Innovation Officer
Buy
125,000
$1.82
$227.50K
SCHULMAN AMY W
8 Apr 2019
Director
Buy indirect
21,635
$16.00
$346.16K
SCHULMAN AMY W
8 Apr 2019
Director
Buy indirect
604,482
$16.00
$9.67M
MCGUIRE TERRANCE
8 Apr 2019
Director
Buy indirect
21,635
$16.00
$346.16K
MCGUIRE TERRANCE
8 Apr 2019
Director
Buy indirect
604,482
$16.00
$9.67M
Currie Mark G
2 Apr 2019
President
Buy
270,107
$14.81
$4.00M

What was left out

Form 4 filings counted 95
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 3
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 10
Transactions with no price 0
Shares from compensation/vesting 32,606,917
Sales filed before the plan box existed 8
History held since 2 Apr 2019